SpeeDx Expand COVID-19 Diagnostics to Include Self-Collected Samples
21.4.2022 19:32:00 EEST | Business Wire | Press release
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have added saliva to the list of validated samples for their Plex PCR® SARS-CoV-2 qPCR diagnostic for COVID-19 sales across Europe#. A preferred sample type for self-collection and compliance testing programs, the saliva claim will expand the utility of the SpeeDx COVID-19 workflow, and in partnership with the Molgen range of automation, will further support ultra-high throughput testing markets.
“Our automation-compatible workflow is very popular with high-volume laboratories along with the flexibility to pair with a range of extant laboratory equipment to maximise instrument capacity,” said Cassandra Ingles, Director of Clinical Operations. “As COVID-19 testing patterns evolve, we will continue to respond to the changing needs of the laboratories we support, expanding claims for important sample types, in addition to making it easier to integrate into laboratory data information systems without the need for third-party software. ”
SpeeDx new head office facilities in Sydney have expanded the company’s manufacturing capacity to support growth in export sales, and as international travel increases, demand for both COVID-19 and other respiratory testing is ongoing. Plex PCR® RespiVirus, a highly multiplexed 11-target Respiratory viral panel that includes Influenza A, Influenza B, and Respiratory Syncytial Virus, can be run in parallel with Plex PCR® SARS-CoV-2 for a more comprehensive testing solution and both are compatible with the SpeeDx Plex Prep™ robotic liquid handler, recently demonstrated to increase throughput 155% and reduce hands-on time 19% compared with a sample-to-answer testing solution.1 Additional respiratory tests are on target to be released this year including Plex PCR® RespiBacteria with targeted detection and differentiation of Bordatella pertussis, B. parapertussis, B. holmesii, and Mycoplasma pneumoniae.
SpeeDx also have a comprehensive range of reagents to support investigation of COVID-19 variants of concern including Plex Prime® SARS-CoV-2 Alpha/Beta/Gamma+* which contains mutations that can distinguish circulating Omicron strains including both BA1 and BA2 variants. Compatible with standard qPCR and liquid handling instrumentation, the Plex Prime® SARS-CoV-2 Genotyping* range is designed to assist laboratories with variant monitoring practices that integrate with their existing SARS-Cov-2 testing workflow, therefore increasing the number of samples screened for variants, improving opportunity to observe deviations in population, and reducing the labour and costs associated with parallel sequence analysis of a subset of positive samples.
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
#not commercially available for use in UK, saliva claim extension under review by TGA for use in Australia
References
Pryce TM et al. Evaluation of a PlexZyme-Based PCR Assay and Assessment of COVID-19 Surge Testing Throughput Compared to Cobas SARS-CoV-2. Pathogens. 2021 Sep; 10(9): 1088.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005847/en/
Contact information
Warwick Need - Director of Sales | SpeeDx
warwickn@speedx.com.au
+61 424 336 577
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom